Gli altri portali
Notizie
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
Medical Robots Market Worth $33.8 billion | MarketsandMarkets™
Browse in-depth TOC on "Medical Robots Market" Browse in-depth TOC on "Medical Robots Market" 164 - Tables 47 - Figures 192 - Pages Medical Robots Market Scope: Soft tissue surgical robotic system is the fastest growing in the medical robots market in 2023. Based on type, the medical robots market is segmented into surgical robotic system, rehabilitation robotic systems, radiosurgery robotic systems, and hospital & pharmacy robotic systems. The surgical robotic...
PR Newswire
18/03/2024
Urbanization, Pollution, and a Shift toward Natural and Organic Products Fueling…
Download the Sample PDF report to explore key market insights and trends: Download the Sample PDF report to explore key market insights and trends: https://www.futuremarketinsights.com/reports/sample/rep-gb-19266 The trend toward natural and organic skincare products and the emergence of niche brands offering alternatives are also reshaping consumer preferences and expanding market opportunities. Specific markets likeIndia,China,Australia,Singapore, andCanadaare...
PR Newswire
18/03/2024
Novonesis will host a conference call regarding 2024 outlook and 2023 pro forma…
Novonesis will host a conference call regarding 2024 outlook and 2023 pro forma financials on March 21 at 9.00am CET. To join the live webcast, please clickhere.To register and receive access details for the conference call, please clickhere. Attachment 2024_Outlook_and_pro_forma_conference_call
Nasdaq GlobeNewswire
18/03/2024
Novo Nordisk A/S - share repurchase programme
Bagsværd, Denmark, 18 March 2024– On 6 February 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2023. Under the...
Nasdaq GlobeNewswire
18/03/2024
Surge in Adoption of Accurate Disease Diagnosis in Clinical Diagnostics…
Download the Sample PDF report to explore key market insights and trends: Download the Sample PDF report to explore key market insights and trends: https://www.futuremarketinsights.com/reports/sample/rep-gb-19253 Multiomic applications in agri-genomics are facilitating advanced crop breeding programs and bolstering agricultural productivity. Environmental monitoring and remediation sectors are embracing multiomic aspects to comprehend ecosystem dynamics and tackle pollution...
PR Newswire
18/03/2024
Lipid-Nanoparticle Based Genomic Medicines Market worth $32.5 Bn by 2031 -…
Lipid-Nanoparticle-Based Genomic Medicines Market Report Scope: Lipid-Nanoparticle-Based Genomic Medicines Market Report Scope: List of Prominent Players in the Lipid-Nanoparticle-Based Genomic Medicines Market: Request for Sample Pages: https://www.insightaceanalytic.com/request-sample/2380 Lipid-nanoparticle (LNP) based genomic medications are an advanced method in the field of delivering drugs and genetic therapies. LNPs are utilized as carriers in these medications to...
PR Newswire
18/03/2024
Quotient Sciences Strengthens Its Top Team with Three New Appointments
New appointments include Dr. Andrew Lewis as Chief Scientific Officer, Kieron Hall as Chief Marketing Officer, and Eric Bironneau as Chief Business Officer who will each play a critical role in Quotient Sciences growth and strategic direction. New appointments include Dr.Andrew Lewisas Chief Scientific Officer,Kieron Hallas Chief Marketing Officer, and Eric Bironneau as Chief Business Officer who will each play a critical role in Quotient Sciences growth and strategic direction...
PR Newswire
18/03/2024
NeuroDerm Announces Publication of Positive Results from Phase 3 BouNDless Trial…
"Orally administered levodopa/carbidopa tablets remain the most essential pharmacological intervention in Parkinson's disease; however, over time, the reliability of its benefits can decrease, leading to the onset of motor fluctuations", said Professor Alberto Espay, Principal U.S. Investigator of the BouNDless trial and Director of the James J. and Joan A. Gardner Family Center for Parkinson's Disease and Movement Disorders at the University of Cincinnati. "We are encouraged by…
PR Newswire
18/03/2024
EDAN and GH Labs Collaborate to Develop AI-Enabled Ultrasound Devices
"We are excited to embark on this transformative journey with GH Labs," said Xicheng Xie, Co-Founder and Vice President of EDAN. "By harnessing the power of AI technology, we aim to make ultrasound examinations more accessible and affordable for communities worldwide." "We are excited to embark on this transformative journey with GH Labs," saidXicheng Xie, Co-Founder and Vice President of EDAN. "By harnessing the power of AI technology, we aim to make…
PR Newswire
18/03/2024
Major shareholder announcement – BlackRock, Inc.
ANNOUNCEMENT NO. 258Major shareholder announcementMajor shareholder announcement – BlackRock, Inc. Pursuant to Section 30 of the Capital Markets Act, it is hereby announced that BlackRock, Inc. has informed ChemoMetec A/S that BlackRock Investment Management (UK) Limited on 14 March 2024, increased its holding of shares and voting rights in ChemoMetec A/S to above 10%, and that the holding thus exceeds the 10 per cent limit in section 38 of the Capital Markets Act...
Nasdaq GlobeNewswire
18/03/2024
Major shareholder announcement – AIM International Mutual Funds
ANNOUNCEMENT NO. 257Major shareholder announcementMajor shareholder announcement – AIM International Mutual Funds Pursuant to Section 30 of the Danish Capital Markets Act, it is hereby announced that Invesco Ltd. has informed ChemoMetec A/S that AIM International Mutual Funds (Invesco International Mutual Funds) on 13 March 2024, increased its holding of shares and voting rights to above 5% of the total share capital and voting rights in ChemoMetec A/S, and that the...
Nasdaq GlobeNewswire
18/03/2024
Major shareholder announcement – Invesco Ltd.
ANNOUNCEMENT NO. 256Major shareholder announcementMajor shareholder announcement – Invesco Ltd. Pursuant to Section 30 of the Danish Capital Markets Act, it is hereby announced that Invesco Ltd. has informed ChemoMetec A/S that Invesco Ltd. on 13 March 2024, increased its holding of voting rights to above 5% of the total voting rights in ChemoMetec A/S, and that the holding thus exceeds the 5 per cent limit in section 38 of the Capital Markets Act.Additional...
Nasdaq GlobeNewswire
18/03/2024
Digital Surgery Technologies Market Worth $6.07 Bn by 2031 - Exclusive Report by…
Digital Surgery Technologies Market Report Scope: Digital Surgery Technologies Market Report Scope: Request for Sample Pages:https://www.insightaceanalytic.com/request-sample/2389 Digital surgery technologies encompass a wide array of innovative tools and solutions aimed at enhancing surgical procedures through the integration of digital technologies such as artificial intelligence, augmented reality, and robotics. These technologies promise greater precision, efficiency, and...
PR Newswire
18/03/2024
Cambrex Nears Completion of 5-year, $100-Million-Dollar Investment Plan, One…
In North America, the 5-year investment strategy included capacity expansions in Charles City, Iowa and High Point, North Carolina, adding clinical and commercial manufacturing suites for small-volume, large-volume and highly potent API manufacturing. To support early development programs, Cambrex expanded its capabilities in Longmont, Colorado, co-locating analytical services in the same facility as drug substance and drug product development. Cambrex also added specialized technologies for…
PR Newswire
18/03/2024
Completion of share buy-back program
Company Announcement COPENHAGEN, Denmark; March 18, 2024 – Genmab A/S (Nasdaq: GMAB) announces that its share buy-back program has been completed on March 15, 2024 On February 14, 2024, Genmab announced the initiation of a share buy-back program to honor our commitments under our Restricted Stock Units program. The share buy-back program was expected to be completed no later than March 15, 2024, and comprised up to 190,000 shares. The following transactions were executed under the...
Nasdaq GlobeNewswire
18/03/2024
Photocure Partner Asieris announces positive international Phase III clinical…
"We are very pleased to see the strong results of this randomized controlled Phase III clinical trial in which Cevira (APL-1702) demonstrated clear benefit in patients with HSIL. Based on the results, treatment with Cevira has the potential to fill an unmet clinical need as an alternative to conventional surgical therapies for HSIL", said Anders Neijber, Photocure's Chief Medical Officer. "At present, Photocure teams are supporting Asieris' to prepare the new drug application…
PR Newswire
18/03/2024
Cristiano Ronaldo Unveils Erakulis: A Revolutionary All-in-One Wellness App -…
Exclusive Offer for Early Adopters Exclusive Offer for Early Adopters "To celebrate this milestone,Erakulisis delighted to extend a special invitation to wellness enthusiasts worldwide. By joining our waitlist through the dedicated landing page, early adopters will secure an exclusive 50% discount on their subscription. This limited-time offer is our way of thanking our community for their support and enthusiasm for a healthier, more balanced life." Features That Set Erakulis...
PR Newswire
18/03/2024
OBI Pharma Announces Poster Presentations at the AACR 2024 Annual Meeting for…
Poster Presentations to highlight the latest research on OBI-992 (anti-TROP2 ADC) and OBI's novel GlycOBI ADC platform /PD properties, and a favorable safety profile across various preclinical animal models. Additionally, preclinical data will be presented on the novel site-specific proprietary GlycOBI™ ADC platform, demonstrating improved in vivo efficacy and stability in animal model studies. These data will be presented at the American Association of Cancer Research (AACR) Annual Meeting...
Nasdaq GlobeNewswire
18/03/2024
Gabather files two new patent applications to secure novel findings on the…
"When approved by USPTO these patent's will further strengthen our drug products and market position, giving Gabather a strong competitive advantage in providing the next generation neuropsychiatric drugs to the patients. We will move forward into clinical trials in patients and identify the right partner for the continued development of GT-002" says Michael-Robin Witt, CEO of Gabather AB. "When approved by USPTO these patent's will further strengthen our drug products and market…
PR Newswire
18/03/2024
Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to…
Enhances Norgine's commitment to bringing transformative therapies to patients in Europe, U.K., Australia, and New Zealand who currently do not have access to a therapy to treat this life altering condition Enhances Norgine's commitment to bringing transformative therapies to patients inEurope, U.K.,Australia, andNew Zealandwho currently do not have access to a therapy to treat this life altering condition RESEARCH TRIANGLE PARK, N.C.and UXBRIDGE,England , March 18,...
PR Newswire
18/03/2024
ONWARD® Medical Successfully Completes Benchmark Testing on Path to…
Third-party tests from leading US lab confirm printed circuit board assembly (PCBA) conforms to prevailing international electrical standards, a requirement for commercial launch THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) EINDHOVEN, the Netherlands, March18, 2024(GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative spinal cord...
Nasdaq GlobeNewswire
18/03/2024
Valneva Announces Extension of the Interest-Only Period of Its Debt Facility…
Reimbursements deferred by 18 months to start in January 2026 instead of July 2024 Saint-Herblain (France), March 18, 2024–Valneva SE(Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced an agreement with funds managed by leading U.S. healthcare investment firms Deerfield Management Company and OrbiMed to extend the interest-only period of its existing loan by eighteen months.Reimbursements of the first $100 million tranche will now start in January...
Nasdaq GlobeNewswire
18/03/2024
Idorsia and Viatris successfully close the transaction for the global research…
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – March 18, 2024Idorsia Ltd (SIX: IDIA) today announced that it has successfully closed the transaction with Viatris Inc. (NASDAQ: VTRS), a global healthcare company, for the global research and development collaboration, focused on the development and commercialization of two innovative compounds, selatogrel and cenerimod, discovered by Idorsia.The upfront consideration of USD 350 million has now been fully paid by...
Nasdaq GlobeNewswire
18/03/2024
Mediwave Earns Global Recognition at GLOMO Awards 2024 for Emergency Response…
The company also showcased its full range of innovations at 4 Years From Now (4YFN), an integral part of the MWC GSMA, which serves as a catalyst for startups taking centre stage in future-proof tech, providing them with invaluable networking opportunities and exposure. The company also showcased its full range of innovations at 4 Years From Now (4YFN), an integral part of the MWC GSMA, which serves as a catalyst for startups taking centre stage in future-proof tech, providing them with...
PR Newswire
18/03/2024
Altri Comunicati
